Source-grounded facts extracted from Entrada Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Entrada Therapeutics, Inc. shareholders approved Approve Amendment No. 1 to the 2021 Employee Stock Purchase Plan (2021 ESPP Amendment) to modify the evergreen provision at the 2026-06-10 meeting.
“The 2021 ESPP Amendment was approved. The results of the stockholders’ vote with respect to such approval were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 16,780,217 7,475,514 3,730 8,930,773”
Entrada Therapeutics, Inc. shareholders approved Approve Amendment No. 1 to the 2021 Stock Option and Incentive Plan (2021 Plan Amendment) to modify the evergreen provision at the 2026-06-10 meeting.
“The 2021 Plan Amendment was approved. The results of the stockholders’ vote with respect to such approval were as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 14,686,713 9,566,186 6,562 8,930,773”
Entrada Therapeutics, Inc. shareholders approved Ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026 at the 2026-06-10 meeting.
“The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified. The results of the stockholders’ vote with respect to such ratification were as follows: FOR AGAINST ABSTAIN 33,132,550 49,650 8,034”
Entrada Therapeutics, Inc. shareholders approved Election of two Class II directors: Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D. at the 2026-06-10 meeting.
“Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D. were duly elected to the Board as Class II directors. The results of the stockholders’ vote with respect to the election were as follows: CLASS II DIRECTOR NOMINEES FOR WITHHELD BROKER NON-VOTES Peter S. Kim, Ph.D. 22,181,490 2,077,971 8,930,773 Bernhardt Zeiher, M.D. 22,315,323 1,944,138 8,930,773”
Entrada Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.
“On May 7, 2026, Entrada Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026 and other corporate updates.”
Maha Radhakrishnan was appointed as Class III director at Entrada Therapeutics, Inc..
“On May 30, 2025, the Board of Directors (the “Board”) of Entrada Therapeutics, Inc. (the “Company”) expanded the size of the Board from six to seven directors and appointed Maha Radhakrishnan, M.D. to the Board as a Class III director, to serve until the Company’s annual meeting of stockholders to be held in 2027 or until her successor is duly elected and qualified, in each case effective as of June 1, 2025.”
Entrada Therapeutics, Inc. announced a restructuring with charges of approximately $2 million affecting research areas (approximately 20%).
“-45, -50, and -51), ocular programs and maturing platform investments. In connection with the new strategic plan, the Company expects to incur aggregate charges of approximately $2 million in total expenses related to the reduction in force, consisting primarily of one-time severance payments and continued healthcare benefits for a specific period of time. The”
Entrada Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $59.1 million, net income $23.5 million.
“of EEV therapeutic candidates targeting DMD and advance EEV-therapeutic candidates in indications beyond neuromuscular disease. Collaboration Revenue: Collaboration revenue was $59.1 million for the first quarter of 2024, compared to $25.3 million for the same period in 2023. The increase was primarily a result of the clinical advancement milestone achieved in the”
Entrada Therapeutics, Inc. reported the year ended December 31, 2023 results: net income Net loss was $6.7 million for the full year of 2023.
“On March 13, 2024, Entrada Therapeutics, Inc. announced its financial results for the year ended December 31, 2023 and other corporate updates.”
Nathan J. Dowden was appointed as President and Chief Operating Officer at Entrada Therapeutics, Inc..
“appointed Nathan J. Dowden, the Company’s Chief Operating Officer, to serve as the Company’s President, effective as of January 1, 2024”
John F. Crowley resigned as member of the Board of Directors at Entrada Therapeutics, Inc..
“On December 5, 2023, John F. Crowley, a member of the Board of Directors (the “Board”) of Entrada Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board, including the Audit Committee of the Board (the “Audit Committee”), on which he serves as a member, and the Compensation Committee of the Board (the “Compensation Committee”), on which he serves as the Chair, effective December 5, 2023.”
Entrada Therapeutics, Inc. reported third quarter ending September 30, 2023 results: revenue $43.7 million, net income $35.5 million.
“milestones, will be sufficient to fund the Company's operating expenses and capital expenditure requirements through 2025. Collaboration Revenue: Collaboration revenue was $43.7 million for the third quarter of 2023. There was no collaboration revenue in the third quarter of 2022. Research & Development (R&D) Expenses: R&D expenses were $22.2 million for the”
Entrada Therapeutics, Inc. amended Sublicense Agreement with Vertex Pharmaceuticals Incorporated valued at Upfront payment of $223.7 million and potential milestone payments up to $485.0 million (effective 2023-10-26).
“Concurrently with the execution of the Amendment to License Agreement, on October 26, 2023, the Company entered into an Amendment No. 1 (the “Amendment to Sublicense Agreement”) to that certain Sublicense Agreement, dated as of December 7, 2022, by and between the Company and Vertex (the “Original Sublicense Agreement” and, as amended by the Amendment to Sublicense Agreement, the “Sublicense Agreement”).”
Entrada Therapeutics, Inc. amended Strategic Collaboration and License Agreement with Vertex Pharmaceuticals Incorporated valued at Upfront payment of $223.7 million and potential milestone payments up to $485.0 million (effective 2023-10-26).
“On October 26, 2023, Entrada Therapeutics, Inc. (the “Company”) and Vertex Pharmaceuticals Incorporated (“Vertex”) entered into Amendment No. 1 (the “Amendment to License Agreement”) to the Strategic Collaboration and License Agreement, dated as of December 7, 2022, by and between the Company and Vertex (the “Original License Agreement” and, as amended by the Amendment to License Agreement, the “License Agreement”).”
Entrada Therapeutics, Inc. entered into Sales Agreement with Cowen and Company, LLC valued at up to $150.0 million (effective 2023-09-29).
“On September 29, 2023, Entrada Therapeutics, Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC, acting as the Company’s agent and/or principal (the “Sales Agent”), with respect to an “at the market offering” program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $150.0 million”
Gina Chapman was appointed as Class III director at Entrada Therapeutics, Inc..
“On August 4, 2023, the Board of Directors (the “Board”) of Entrada Therapeutics, Inc. (the “Company”) appointed Gina Chapman to the Board as a Class III director, effective September 1, 2023”
Entrada Therapeutics, Inc. reported second quarter 2023 results: net income Net loss was $25.9 million for the second quarter of 2023.
“Net loss was $25.9 million for the second quarter of 2023, compared to a net loss of $23.2 million for the same period in 2022.”
Entrada Therapeutics, Inc. reported second quarter 2023, quarter ended June 30, 2023 results: revenue 18.2 million, net income -25.9 million.
“Collaboration revenue was $18.2 million for the second quarter of 2023.”
Entrada Therapeutics, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm at the 2023-06-08 meeting.
“Proposal No. 2 The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified. The results of the ratification were as follows: FOR AGAINST ABSTAIN 26,634,250 606 10”
Entrada Therapeutics, Inc. shareholders approved Election of two Class II directors at the 2023-06-08 meeting.
“Proposal No. 1 Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D. were duly elected to the Company’s Board as Class II directors. The results of the election were as follows: CLASS II DIRECTOR NOMINEE FOR WITHHELD BROKER NON-VOTES Peter S. Kim, Ph.D. 24,512,848 245,047 1,876,971 Bernhardt Zeiher, M.D. 24,696,429 61,466 1,876,971”
Todd Foley resigned as member of the Board of Directors at Entrada Therapeutics, Inc..
“On June 7, 2023, Todd Foley notified Entrada Therapeutics, Inc. (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”), effective as of June 7, 2023.”
Entrada Therapeutics, Inc. reported first quarter ending March 31, 2023 results: revenue $25.3 million, net income ($6.7) million.
“development of EEV-therapeutic candidates targeting Duchenne as well as other indications beyond neuromuscular diseases. Collaboration Revenue: Collaboration revenue was $25.3 million for the first quarter of 2023 following the closing of the Vertex Agreement in February 2023. There was no collaboration revenue in the first quarter of 2022. Research &”
Bernhardt Zeiher was appointed as Director at Entrada Therapeutics, Inc..
“Effective as of April 4, 2023, the Board of Directors (the “Board”) of Entrada Therapeutics, Inc. (the “Company”) expanded the size of the Board from seven to eight directors and appointed Bernhardt Zeiher, M.D. to the Board as a Class II director, to serve until the annual meeting of stockholders held in 2023 or until his successor is duly elected and qualified.”
Entrada Therapeutics, Inc. reported the fourth quarter and full year ending December 31, 2022 results: net income Net loss was $24.6 million for the fourth quarter of 2022 and $94.6 million for the full year of 2022.
“Entrada Therapeutics, Inc. announced its financial results for the year ended December 31, 2022 and other corporate updates.”
Entrada Therapeutics, Inc. entered into Stock Purchase Agreement with Vertex Pharmaceuticals Incorporated valued at Aggregate purchase price of approximately $26.3 million for 1,618,613 shares at $16.26 per share. (effective 2022-12-07).
“Concurrently with the execution of the License Agreement, on December 7, 2022, the Company entered into a stock purchase agreement (the “Stock Purchase Agreement”) with Vertex, pursuant to which Vertex has agreed to purchase from the Company 1,618,613 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share, in a private placement transaction for an aggregate purchase price of approximately $26.3 million or $16.26 per share.”
Entrada Therapeutics, Inc. entered into Strategic Collaboration and License Agreement with Vertex Pharmaceuticals Incorporated valued at Upfront payment of $223.7 million and equity investment of $26.3 million; potential milestones up to (effective 2022-12-07).
“Item 1.01. Entry into a Material Definitive Agreement. On December 7, 2022, Entrada Therapeutics, Inc. (the “Company”) and Vertex Pharmaceuticals Incorporated (“Vertex”) entered into a Strategic Collaboration and License Agreement (the “License Agreement”) pursuant to which the Company granted Vertex an exclusive worldwide license to research, develop, manufacture, commercialize ENTR-701, the Company’s intracellular Endosomal Escape Vehicle (“EEV”)-based therapeutic candidate for the treatment of myotonic dystrophy type 1 (“DM1”) that targets expanded CUG repeats in DM1 protein kinase (DMPK) mRNA transcripts, as well as any additional EEV-based therapeutic candidates that may be identified by the Company for the potential treatment of DM1 in the course of the parties’ global research collaboration. The License Agreement provides for a four-year global research collaboration under which Vertex will fund the Company’s continued pre-clinical development of ENTR-701, as well as additional”
Entrada Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income Net loss for the third quarter of 2022 was $25.1 million.
“Net loss for the third quarter of 2022 was $25.1 million, compared to $14.4 million for the same period of 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.